Glioblastoma multiforme (GBM) is the most common primary brain tumour in adults and one
of the most aggressive cancers in man. Despite technological advances in surgical …

Glioblastoma multiforme is the most malignant and aggressive type of brain tumor, with a
mean life expectancy of less than 15 months. This is due in part to the high resistance to …

We evaluated the anti-tumor activity and safety of erlotinib, a receptor tyrosine kinase
inhibitor of the epidermal growth factor receptor, plus sirolimus, an inhibitor of the …

Due to its molecular heterogeneity and infiltrative nature, glioblastoma multiforme (GBM) is
notoriously resistant to traditional and experimental therapeutics. To overcome these …

The poor response of glioblastoma to current treatment protocols is a consequence of its
intrinsic drug resistance. Resistance to chemotherapy is primarily associated with …

Background Recent studies have proposed several gene signatures as biomarkers for
different grades of gliomas from various perspectives. However, most of these genes can …

Resveratrol (Res), a natural polyphenolic compound, has anticancer activity in a variety of
cancers. In the present study, the antitumor effect and underlying molecular mechanism of …

Objective In the development of immunotherapies in gliomas, the tumor microenvironment
(TME) needs to be investigated. We aimed to construct a prognostic microenvironment …

Radiation therapy (RT) is one of the most effective and widely used treatment methods for
glioblastoma multiforme (GBM). However, its efficacy is often compromised by the inherent …

Background: Insulin-like growth factor (IGF)–binding protein (IGFBP) isoforms have been
implicated in the pathogenesis of human neoplasms including glioma. In view of this, we …